Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NowPatient vs TelePeptide

NowPatient
Graded #217

Higher grade

vs+3.200000000000003
TelePeptide
Graded #273

Lower grade

The verdict

NowPatient takes it — 65.5/100 to 62.3/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTelePeptide +9
35
44
Dose & formulationNowPatient +18
93
75
Clinical oversightTelePeptide +1
86
87
Labs & monitoringEven
54
54
FulfillmentTelePeptide +7
70
77
Contract termsNowPatient +35
55
20
NowPatient · left barTelePeptide · right bar

The numbers

MetricNowPatientTelePeptide
WeighScore65.5/10062.3/100
GradeCC
Scorecard rank#217#273
Semaglutide$1,349/mo (brand Wegovy)$199/mo (starting dose, annual plan, compounded oral)
Tirzepatide$1,069/mo (brand Mounjaro, promotional rate)$219/mo (starting dose, annual plan, compounded oral)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
NowPatient

Graded #217 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)
TelePeptide

Graded #273 · C

Strengths

  • LegitScript-certified (seal ID 49966407); 503A-licensed compounding pharmacies
  • All-inclusive from $169/mo annual — physician eval + Rx + medication + shipping, no hidden fees
  • Broadest formulation menu: injectable sema/tirz, oral dissolvable tablets, sema+naltrexone, microdose combos
  • 24/7 care team messaging + regular check-ins + dosage adjustments included at every tier
  • 48 states + DC coverage (excludes only AK + MS); no insurance required; cancel anytime

Where it loses points

  • Compounded medications are not FDA-approved; no pharmacy partner named publicly
  • Monthly billing costs more — $199/mo (monthly) vs $169/mo (annual) for semaglutide injectable; best rate requires annual prepay
  • Labs not included in any plan
  • Founder disclosed by first name only (Ahmed); no physician names or clinical leadership disclosed publicly
  • Tirzepatide injectable at $249/mo (monthly billing) is above the compounded market average

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard